Predictors and potentiators of psychedelic-occasioned mystical experiences

Mystical experiences are described by the authors as states characterised by unity, transcendence of time and space, intense positive mood, a sense of sacredness, ineffability and a noetic quality (a felt sense that what is revealed is true). Historically reported across cultures, these experiences can occur spontaneously but are reliably occasioned by psychedelic substances when the psychological and environmental context is supportive. Earlier research links the occurrence and intensity of psychedelic-occasioned mystical experiences to durable positive changes in well-being, prosocial attitudes, meaning in life and reductions in clinical symptoms across conditions such as depression, addiction and existential distress. This review sets out to examine the factors that predict or potentiate the occurrence and intensity of mystical experiences during psychedelic sessions, and to consider practical ways these factors might be optimised while noting elements that are negatively associated with such experiences. Gandy frames mystical experiences as a key mediator of long-term therapeutic benefit from psychedelics and aims to collate evidence on pharmacological, psychological and contextual determinants (for example: set and setting, dose, trait absorption, drug type, intention, surrender and acceptance), as well as potential augmenting practices such as music, meditation and nature-based settings. The paper also highlights concerns about suggestibility and priming and proposes avenues for future research to refine understanding and clinical practice.

The extracted text does not present a discrete Methods section or a detailed description of search and inclusion criteria. The paper reads as a narrative review that synthesises findings from controlled trials, pooled analyses, observational studies, naturalistic surveys and retreat-based reports rather than a systematic meta-analysis with a reported search strategy. Sources discussed include randomized, double-blind, placebo-controlled psilocybin trials (including work conducted at Johns Hopkins), early experimental studies (for example Pahnke's chapel study), pooled analyses (a cited pooled analysis of 23 studies involving 409 psilocybin sessions and 261 healthy volunteers), naturalistic self-report surveys of mescaline, DMT, psilocybin and 5-MeO-DMT users, observational retreat studies administering bufotoxin-derived 5-MeO-DMT, and small experimental comparisons of music types. The author integrates quantitative outcome rates and qualitative considerations across these diverse designs but does not report formal risk-of-bias assessment, databases searched, or selection methods in the extracted text.

Gandy organises the empirical evidence around predictors (factors associated with greater likelihood or intensity of mystical experiences) and potentiators (practices or settings that may augment occurrence or benefits). Set and setting: Contextual factors strongly influence whether a psychedelic occasion yields a mystical experience. Studies contrasted highly supportive, prepared clinical contexts (for example Johns Hopkins trials) with less-structured hospital or naturalistic settings and found markedly different rates of complete mystical experiences (examples cited include 61% in a well-prepared psilocybin study versus 12.5% in one LSD study). A supportive context typically involved preparatory sessions, reclining with eyeshades, curated music, compassionate interpersonal support, and recruitment of spiritually interested volunteers; such conditions were associated with higher rates and intensity of mystical experiences. Conversely, exposure to language during the acute session and music with recognisable lyrics were reported as negatively associated with mystical experiences. Drug dosage: Dose is a key predictor. Higher psilocybin doses were associated with higher mystical-experience scores and greater likelihood of ‘‘complete’’ mystical experiences, though higher doses also increased adverse reactions. The review reports estimates indicating a psilocybin threshold above which ‘‘complete’’ mystical experiences become more common (text cites an estimate of 350 mg kg−1 bodyweight or an absolute 24.5 mg/70 kg, and notes that 30 mg/70 kg produced complete experiences in 61% in a seminal study). A dose of about 25 mg psilocybin is described as a commonly used clinical compromise for maximizing chances of mystical experiences while limiting adverse events. Individual variability and the need for personalised dose escalation are emphasised, especially for substances such as 5-MeO-DMT. Trait absorption and related traits: Trait absorption—the tendency to become fully immersed in sensory or imaginative experiences—emerged as one of the most important psychological predictors alongside set and dose. Absorption correlates with openness to experience and self-transcendence, and higher absorption predicts mystical and spiritual experiences. The review notes evidence that absorption can be enhanced (state and trait) through practices and by the session context; a single 25 mg/70 kg psilocybin experience was reported to increase trait absorption for at least a month in one study. Drug type: Different psychedelics vary in consistency of eliciting mystical experiences. Naturalistic survey figures cited include complete mystical experiences in 30% of mescaline users, 37% of DMT users, 47% of psilocybin users and 57% of 5-MeO-DMT users. When 5-MeO-DMT was administered in supportive contexts, reported rates were higher (75%–83% in cited observational and retreat contexts). The author notes selection biases in internet surveys and variability in active ingredient content (for example psilocybin content of mushrooms, concentration variability in bufotoxin), but overall suggests 5-MeO-DMT may occasion mystical experiences more consistently in supportive settings. Intention, surrender and acceptance: Approaching a session with clear emotional or spiritual intention was associated with greater likelihood of mystical-type experiences. The state of surrender—volitionally letting go—and acceptance (a non-judgemental stance) were both predictive of mystical experiences. Feelings of trust and rapport with guides, cultivated prior to the session, were described as important prerequisites for surrender and thus for the occurrence of mystical experiences. Music: Music is portrayed as a central component of many therapeutic sessions and is associated with eliciting awe and transcendence. One survey of experienced psilocybin facilitators identified musical features conducive to mystical experiences (e.g. predictable phrase structure, continuous forward motion, lower perceptual brightness). A small study (n=10) suggested overtone-based music might produce stronger mystical scores than Western classical compositions, but results were not statistically significant and the sample was tiny. Meditation and spiritual practices: Pre-existing and newly cultivated contemplative practices appear to potentiate mystical experiences. A controlled study in experienced meditation practitioners during a five-day retreat reported 95% of participants receiving psilocybin reported a complete mystical experience (dosage reported as 315 mg kg−1 bodyweight or 21.76 ± 3.8 mg). Another double-blind trial added months-long spiritual practice to support and observed higher Mysticism Scale scores and sustained psychological benefits at 6 months. Shorter practice windows (1–2 months) of meditation, journaling and awareness exercises were also associated with higher ratings of the spiritual significance of psilocybin sessions. The review highlights reciprocal reinforcement between meditation practice and psychedelic-induced ego-dissolution. Nature-based settings: Immersion in natural environments was linked to increased awe, absorption and feelings of interconnectedness and therefore may potentiate mystical experiences and pro-environmental and prosocial outcomes. Studies cited and anecdotal accounts suggest nature-based settings can amplify both acute and enduring benefits. Adverse and negative associations: Higher doses increased the risk of challenging acute reactions (for example extreme fear, delusions, paranoia). State-level psychological distress prior to a session was negatively correlated with oceanic boundlessness (a core unitive component). The author also raises concerns about enhanced suggestibility, potential for directive priming by clinicians, spiritual emergency or ‘‘spiritual narcissism’’ following repeated unexplained experiences, and the need to avoid imposing clinicians’ own beliefs.

Gandy interprets the assembled evidence to place mystical experiences as central mediators of sustained psychological benefits following psychedelic administration in both healthy and clinical samples. The review argues that a psychedelic is best understood as a catalyst that, together with psychological and environmental context, determines experiential outcomes; optimising set and setting, dose, psychological readiness (including absorption, intention, surrender and acceptance), and supportive practices (music, meditation, nature immersion) increases the likelihood and depth of mystical experiences and thereby may enhance long-term outcomes. The author situates these conclusions relative to prior research by contrasting studies with highly optimised contexts (which yielded higher rates of complete mystical experiences) against studies conducted in less supportive settings. Gandy emphasises that certain substances (for example 5-MeO-DMT) may be particularly potent in eliciting mystical experiences when administered in supportive contexts and that contemplative training appears to have a potentiating effect, as suggested by retreat-based and controlled studies. Key limitations and uncertainties are acknowledged. The paper notes that widely used measurement instruments (MEQ, Mysticism Scale) have limited resolution and may be ill-suited for very intense, short-acting experiences; the extracted text also points out variability and potential selection bias in naturalistic surveys, inconsistencies in dosage reporting (for example variable psilocybin content in mushrooms and variable 5-MeO-DMT concentrations in bufotoxin), and the absence of a standardised methodology for many of the cited studies. The review further cautions about the ethical and therapeutic risks associated with suggestibility and priming, and flags the possibility of adverse sequelae such as spiritual emergencies and spiritual bypassing where integration is inadequate. For practice and research, the author recommends efforts to recruit more heterogeneous samples, to use finer-grained phenomenological methods (for example micro-phenomenological interviews) to capture variation in mystical experiences, and to experimentally test interventions that may enhance absorption or integrate contemplative training into therapeutic protocols. Other proposed research directions include systematic evaluation of nature-based settings, different musical approaches, rhythmic chanting, virtual reality, and psychological frameworks that promote flexibility (for example ACT and ACE models). Finally, Gandy suggests that interventions encouraging engaged living and ecotherapy may synergise with the aftereffects of mystical experiences to sustain prosocial and well-being outcomes.

Gandy concludes that psychedelics have a distinctive capacity to occasion mystical experiences when the right combination of drug, dose, mindset and environment is present. The review summarises that set and setting, dose, trait absorption, drug type, intention, surrender and acceptance, and adjunctive practices such as meditation, music and nature immersion all influence the occurrence and impact of these experiences. Caution is emphasised regarding suggestibility and the risk of directive priming; clinicians should foster open, non‑directive, client-centred approaches and ensure integration. The author closes by noting that while mystical experiences are important predictors of long-term benefit, the evidence base remains nascent and further rigorous research is required to safely maximise their therapeutic potential.